Burning Rock Biotech Ltd (BNR) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Burning Rock Biotech Ltd stock (BNR) is currently trading at $19.81. Burning Rock Biotech Ltd PS ratio (Price-to-Sales) is 0.38. Analyst consensus price target for BNR is $4.03. WallStSmart rates BNR as Sell.
- BNR PE ratio analysis and historical PE chart
- BNR PS ratio (Price-to-Sales) history and trend
- BNR intrinsic value — DCF, Graham Number, EPV models
- BNR stock price prediction 2025 2026 2027 2028 2029 2030
- BNR fair value vs current price
- BNR insider transactions and insider buying
- Is BNR undervalued or overvalued?
- Burning Rock Biotech Ltd financial analysis — revenue, earnings, cash flow
- BNR Piotroski F-Score and Altman Z-Score
- BNR analyst price target and Smart Rating
Burning Rock Biotech
📊 No data available
Try selecting a different time range
Smart Analysis
Burning Rock Biotech Ltd (BNR) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Burning Rock Biotech Ltd (BNR) Key Strengths (1)
Paying less than $1 for every $1 of annual revenue
Supporting Valuation Data
Burning Rock Biotech Ltd (BNR) Areas to Watch (7)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Revenue growing slowly at 0.20% annually
Micro-cap company with very limited liquidity and high volatility
Fairly priced relative to book value
Moderate institutional interest at 45.30%
Supporting Valuation Data
Burning Rock Biotech Ltd (BNR) Detailed Analysis Report
Overall Assessment
This company scores 29/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 1 register as strengths (avg 10.0/10) while 7 fall into concern territory (avg 2.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales. Valuation metrics including Price/Sales (0.38) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Book (2.64) suggest expensive pricing. Growth concerns include Revenue Growth at 0.20%, which may limit upside. Profitability pressure is visible in Return on Equity at -9.92%, Operating Margin at -9.53%, Profit Margin at -10.30%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -9.92% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 0.20% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
BNR Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
BNR's Price-to-Sales ratio of 0.38x sits near its historical average of 0.42x (29th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 25% below its historical high of 0.51x set in Mar 2026, and 19% above its historical low of 0.32x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~0.5x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Burning Rock Biotech Ltd (BNR) · HEALTHCARE › DIAGNOSTICS & RESEARCH
The Big Picture
Burning Rock Biotech Ltd is in a turnaround phase, with management focused on restoring profitability. Revenue reached 540M with 0% growth year-over-year. The company is currently unprofitable, posting a -10.3% profit margin.
Key Findings
Generating 16M in free cash flow and 16M in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -10.3% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Sector dynamics: monitor DIAGNOSTICS & RESEARCH industry trends, competitive moves, and regulatory changes that could impact Burning Rock Biotech Ltd.
Bottom Line
Burning Rock Biotech Ltd is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 11:40:16 AM
About Burning Rock Biotech Ltd(BNR)
NASDAQ
HEALTHCARE
DIAGNOSTICS & RESEARCH
China
Burning Rock Biotech Limited primarily develops and provides screening tests for cancer therapies in the People's Republic of China. The company is headquartered in Guangzhou, China.